The CD117 (KIT) protein is overexpressed in many human neoplasms including adenoid cystic carcinoma of salivary glands. To evaluate the function of c-kit-activating mutations in adenoid cystic carcinoma of the salivary gland, we studied 14 cases (13 primary, 1 cervical lymph node metastasis) from our institution. KIT protein expression was evaluated by immunohistochemistry using formalin-fixed paraffin-embedded tissue. Mutational analyses of c-kit extracellular (exon 9), juxtamembrane (exon 11) and tyrosine kinase domains (exons 13 and 17) were performed by polymerase chain reaction, clonal selection and DNA sequencing. All 14 cases demonstrated strong KIT expression by immunohistochemistry. Molecular analysis was successful in 8 of 14 cases, and c-kit missense point mutations were detected in seven of eight cases (88%) including seven in exon 11, two in exon 9, two in exon 13 and two in exon 17. Eight silent point mutations were detected in five cases. Two cases contained missense mutations in more than one exon. Different mutations were found in the primary tumor and the cervical lymph node metastasis of one patient. Point mutations in domains similar to those described in gastrointestinal stromal tumors were detected, including Pro551Leu and Lys558Glu (5 0 end of exon 11), Leu576Phe (3 0 end of exon 11), Val643Ala (exon 13) and Asn822Ser (exon 17). Additional novel point mutations in exons 9, 11, 13 and 17 were also identified. This study is the first to report c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Identification of such potential gain-of-function mutations in exon 11, and less frequently in exons 9, 13 and 17, suggests that KIT may be involved in the pathogenesis of adenoid cystic carcinoma of salivary glands. Our study raises a prospect of correlation of c-kit mutation and a potential treatment of adenoid cystic carcinoma with tyrosine kinase inhibitor (imatinib).
CD117 (KIT) is a type III receptor tyrosine kinase that is activated by binding of its ligand, stem cell factor. In humans, the c-kit gene has been mapped to chromosome 4q12 adjacent to the highly homologous plateletderived growth factor receptor (PDGFR). [1] [2] [3] Binding of stem cell factor initiates a phosphorylation cascade that ultimately leads to activation of various transcription factors that regulate apoptosis, cell differentiation and proliferation. KIT protein expression is important in the development of normal human tissues and in many human neoplasms including mastocytosis, gastrointestinal stromal cell tumors, melanoma, breast cancer, both small-cell and non-small-cell lung cancers, gynecologic cancers, thyroid neoplasms, myeloid leukemia and seminomas. 4, 5 Recently, KIT expression has been identified in seven types of salivary gland tumors: adenoid cystic carcinomas, epithelial-myoepithelial carcinomas, carcinosarcomas, basal cell adenocarcinomas, acinic cell carcinomas, polymorphous low-grade adenocarcinomas, lymphoepithelioma-like carcinomas and in the lumina of pleomorphic adenomas. 5, 6 This is in contrast to other salivary gland carcinomas and normal salivary lobules. Of these seven tumors, KIT expression has been most extensively documented in adenoid cystic carcinomas with a frequency of expression ranging from 67 to 100%. [7] [8] [9] In addition, using fluorescent in situ hybridization analysis, copy number gains have been reported in 6.1% of cases.
Pathologic activation of the KIT protein through gain-of-function mutations in the c-kit gene has been demonstrated in hematopoietic malignancies (mastocytosis, acute myeloid leukemia), germ cell tumors (seminomas) and tumors arising from interstitial cells of Cajal (gastrointestinal stromal tumors). A great majority of c-kit mutations cluster in the juxtamembrane domain (exon 11) and tyrosine kinase 2 domain (exon 17), and less frequently in extracellular domains (exons 2, 8 and 9) and tyrosine kinase 1 domain (exons 13 and 14) . Some c-kit mutations have specific clinicopathologic significance and differ in response to tyrosine kinase inhibitor treatment/inhibitor sensitivity. For instance in gastrointestinal stromal tumors, mutations in the juxtamembrane domain (exon 11) or the extracellular domain (exon 9) are responsive to tyrosine kinase inhibitor (imatinib) therapy, whereas mutations in exon 13 (that is, V654A and W670I) and exon 17 (D816V and T823D) are predominately imatinib resistant. [10] [11] [12] Moreover, resistance often develops within a few years in gastrointestinal stromal tumors treated with imatinib due to acquisition of secondary c-kit mutations and c-kit gene amplifications. 13 The genetic explanation for KIT overexpression in adenoid cystic carcinoma of the salivary gland remains to be elucidated. To the best of our knowledge, only a few studies to date have looked for activating mutations in the c-kit gene in adenoid cystic carcinomas. 4 To examine the function of c-kit tumorigenesis in adenoid cystic carcinoma, we examined 14 cases of primary adenoid cystic carcinoma of the salivary gland for KIT protein expression and for c-kit gene mutations in exons 9, 11, 13 and 17 by polymerase chain reaction (PCR) amplification, clonal selection and DNA sequencing. This more sensitive methodology allowed us to identify multiple mutations in the c-kit gene.
Materials and methods

Case Selection
Fourteen cases of primary adenoid cystic carcinoma of the salivary gland were identified through a medical record search of patients who underwent biopsy or surgery for salivary gland tumors between 2000 and 2007 at the University of Florida and Shands Hospital. All cases were reviewed by a head and neck pathologist to assure accuracy of the diagnosis of adenoid cystic carcinoma. Adenoid cystic carcinomas of the salivary gland were graded as low grade and high grade based on the predominant histologic pattern observed. Tumors with predominantly tubular and/or cribriform pattern and with solid areas o30% were considered low grade (favorable histology). Tumors with X30% solid component were classified as high grade (unfavorable histology). This study was approved by the University of Florida Institutional Review Board.
Immunohistochemistry
Paraffin slides (4 mm) were cut and placed on plus slides and were dried for 2 h in a 601C oven. The slides were then placed on the Ventana Benchmark automated immunostainer where they were dewaxed and heat-induced epitope retrieval was performed with Ventana's CC1 retrieval solution. Primary antibody anti-CD117, c-kit (C-Term) (YR145; Cell Marque, Rocklin, CA, USA) prediluted rabbit monoclonal antibody, was applied to sections at 421C for 16 min. Presence of the antigen was visualized by using the ultraView DAB detection kit (Ventana Medical Systems Inc., Tucson, AZ, USA). Slides were counterstained with Ventana hematoxylin taken off the stainer and then were dehydrated, cleared and mounted with permanent mounting media.
Mutation Analysis
Tumor-rich areas of unstained, 10 mm paraffin slides were microdissected for each case. Genomic DNA was extracted using TrimGen DNA extraction kit (Trim Gen, Sparks, MD, USA) in accordance with the manufacturer's instructions.
All cases were subjected to a PCR reaction using primers designed to amplify exons 9, 11, 13 and 17 of the c-kit gene, as outlined by Antonescu et al.
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These products were amplified for 38 cycles on a DNA Thermal cycler (Applied Biosystems, Foster City, CA, USA) as follows: (1) 941C for 4 min; (2) 941C for 30 s, 531C for 30 s, 721C for 30 s (38 cycles) and (3) 721C for 3 min. The amplification reactions were performed in a total volume of 25 ml. The reaction mixture contained 1 ml of DNA, 0.5 ml of the forward and reverse primers (10 mM), 0.25 ml of Taq polymerase (Applied Biosystems), 0.5 ml of dNTP (10 mM), 0.5 ml of MgCl 2 (25 mM), 5 ml of 5 Â PCR buffer and 17.25 ml of PCR grade sterile water.
The PCR products were isolated through electrophoresis on a 1% agarose gel stained with ethidium bromide. PCR products were purified using the Qiaex II Gel Extraction kit (Qiagen Inc., Valencia, CA, USA) before cloning. Cloning was performed c-kit mutations in adenoid cystic carcinoma L Vila et al using the Promega T/A Cloning kit (Promega, Madison, WI, USA). Two to five colonies were selected per exon from each tumor for DNA sequencing. DNA sequencing was performed at the University of Florida Interdisciplinary Center for Biotechnology Research using a 96-well plate format and M13 forward primer. DNA sequences were analyzed using the National Center for Biotechnology Information human c-kit gene sequence (mRNA X06182) and BLAST software to determine the location and type of mutation within each exon.
Results
The clinicopathologic data for the 14 cases of adenoid cystic carcinoma of the salivary gland are illustrated in Table 1 . The mean patient age was 59 years (range 45-86 years) and the male to female ratio was 1:1.5. Tumor sites included the parotid gland (n ¼ 4), sublingual gland (n ¼ 2), minor salivary glands of the palate (n ¼ 2), tongue (n ¼ 1), maxillary and ethmoid sinuses (n ¼ 2), nasopharynx (n ¼ 1) and orbit (n ¼ 1). In addition, metastasis to an ipsilateral Level 2A neck lymph node was included for study in one patient with primary adenoid cystic carcinoma of the soft palate (cases 7a and 7b in Table  1 ). The average tumor size was 2.5 cm. Histologically, nine cases contained 'favorable' histology with tubular and/or cribriform growth pattern and five cases contained 'unfavorable' histology with greater X30% solid pattern. All 14 cases of adenoid cystic carcinoma of the salivary gland demonstrated strong KIT protein expression by immunohistochemistry in the tumor cells (Figure 1 ) with no immunoreactivity in the adjacent normal salivary gland tissue. Extraction of genomic DNA was successful in 8 out of 14 cases. In five cases, the PCR product was too weak to allow for successful DNA extraction/purification. One case was discarded due to possible crosscontamination with another tumor sample.
The results of the mutational analyses are summarized in Table 2 . Overall, c-kit missense point mutations, resulting in the substitution of one amino acid for a different amino acid, were detected in seven of eight cases (88%) as follows: seven in exon 11, two in exon 9, two in exon 13 and two in exon 17. In addition, eight silent mutations resulting in no change in amino-acid sequence were detected in five cases. The types of point mutations detected were heterogeneous, but the majority were clustered in exon 11 near the 5 0 and 3 0 ends (Table 3) . Analyses of the cervical lymph node metastasis of one patient (case 7b) revealed different mutations in the metastatic tumor (Asp496Val) vs primary tumor (Lys558Glu, Glu562Val, Phe591Leu and Leu813Pro). Two tumors contained mutations in more than one exon (cases 7a and 10). Mutations in exons 9, 11 and 13 were found in both low-and high-grade tumors. No differences were seen in the types of mutations found between low-and high-grade tumors in this study.
Discussion
This study is the first to report c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Activating mutations in the c-kit gene have been shown in a spectrum of human tumors including kinase domain mutations in mast cell neoplasms and seminomas and extracellular and transmembrane mutations in acute myeloid leukemia and myeloproliferative disorders. In gastrointestinal stromal tumors, 65-92% of tumors are reported to harbor KIT-activating mutations, the majority of which are localized to the juxtamembrane region involving exon 11. 18, 19 The majority of exon 11 mutations are clustered within the classic hotspot region of the 5 0 end involving codons 550-560, however, a second hot spot at the 3 0 end involving codons 576-590 has been described by Antonescu et al. 17 These include frame deletions of one to several codons (typically involving codons 557-560), point mutations and internal tandem duplications (typically involving the 3 0 end). In our study, point mutations in exon 11 were most frequently detected and were clustered in the 5 0 and 3 0 regions of exon 11. The types of point mutations were heterogeneous; however, substitutions similar to those described in gastrointestinal stromal tumors were detected including Leu576Phe in exon 11 and substitutions involving codons 551 and 558 (Pro551-Leu and Lys 558Glu). 17, 20, 21 Novel exon 11 mutations detected in our study included Glu562Val, His580-Tyr, Phe584Leu and Phe591Leu.
Mutations in exons 9, 13 and 17 were less frequently detected than exon 11 mutations. These are considered rare in gastrointestinal stromal tumors with a reported frequency of less than 10%, but are seen more commonly in hematopoietic malignancies and germ cell neoplasms. [22] [23] [24] Exon 13 mutations tend to occur in the vicinity of codon 642, with the 1945 A4G substitution leading to Lys642-Glu mutation being the most common. 22 We detected the variant Val643Ala mutation observed in gastrointestinal stromal tumors. In addition, exon 17 mutations preferentially involve codon 822 with the 2487T4A substitution being most frequent. 22 We detected a variant mutation in adenoid cystic carcinoma consisting of 2486T4A substitution leading to Asn822Ser. Additional novel mutations included Asp496Val and Asn512Asp in exon 9, c-kit mutations in adenoid cystic carcinoma L Vila et al Ser639Pro in exon 13, Leu813Pro in exon 17. We did not detect any insertions or duplications in exon 9, as have been reported involving codons 502-503 AY and 506-508 FAF. 17, [23] [24] [25] In two patients, we detected more than one mutation in exon 11. In addition, in two cases with exon 11 mutations, we detected additional mutations in exons 9 and 17, respectively. Interestingly, in one patient whose primary tumor contained multiple point mutations in exons 11 and 17 (Lys558Glu, Glu562Val, Phe591Leu and Leu813Pro), we detected a different mutation in exon 9 (Asp496Val) in the cervical level IIA lymph node metastasis. In general, involvement of different c-kit domains is mutually exclusive; however, our results are in keeping with a few studies, which have reported multiple c-kit mutations within the same tumor. [26] [27] [28] Similar to our study, Andersson et al 27 found multiple KIT mutations involving different exons and also loss or addition of mutations in the tumor metastases compared with the primary tumors. Sakurai et al 28 likewise identified different mutations in different samples from the same patient. These findings demonstrate the heterogeneity of KIT mutations found within cells of the same tumor population.
Our results differ from four previous studies that did not detect KIT mutations in adenoid cystic carcinomas of the salivary gland and lung. 4, 5, [14] [15] [16] These studies used direct PCR sequencing techniques, which is by far, the most widely used; however, direct PCR sequencing lacks significant sensitivity compared to subcloning of the DNA products, because of the heterogeneous DNA from both normal and tumor samples. The high percentage of mutations detected in our study may be attributed to the increased sensitivity obtained through cloning of PCR products and selection of multiple colonies per each exon for DNA sequencing. The The first row depicts the wild-type sequence of c-kit exon 11 (codons 550-592) from the 5 0 to 3 0 ends (left to right). Missense point mutations resulting in amino-acid substitutions are in bold, whereas silent mutations resulting in no amino-acid change are in italics.
c-kit mutations in adenoid cystic carcinoma cloning selection allowed us to sequence the single species of DNA fragment for each sequencing reaction.
Our study demonstrates the presence of c-kit gene mutations in adenoid cystic carcinomas. The functional significance of these mutations for KIT protein remains to be determined through many cell biology studies. Even less is known about how these mutations are related to potential treatment. There is conflicting data regarding the function of tyrosine kinase inhibitor treatment in adenoid cystic carcinoma. The results of Hotte et al 29 showed no evidence of objective response among 15 patients treated with imatinib mesylate. Pfeffer et al 30 and Ochel et al 31 similarly showed no therapeutic response of locally advanced or metastatic adenoid cystic carcinomas to imatinib. These studies assessed response to tyrosine kinase inhibitor treatment using tumors with strong c-kit immunohistochemical expression; however, they did not assess genetic alterations of the c-kit gene. Lin et al 15 observed an unexpected rate of progression of metastatic adenoid cystic carcinoma during 2-3 weeks of treatment with imatinib in five tumors that contained no detectable c-kit or PDGFR-a mutations. Based on their results, the authors concluded that use of imatinib to treat cancers without c-kit or PDGFR-a mutations should be approached with caution. However, preliminary results of a phase II multicenter trial by Faivre et al 32 have demonstrated that imatinib may have, at least in a subset of patients, antitumor activity in adenoid cystic carcinoma. Alcedo et al 33 also reported two successfully treated cases of adenoid cystic carcinoma of the salivary gland with imatinib. Further studies are needed to investigate the type of KIT mutations harbored by responders compared to nonresponders, as this may be of prognostic value in assessing response to tyrosine kinase inhibitor treatment.
In summary, this study is first to report the presence of c-kit gene mutations in primary adenoid cystic carcinoma. These potential gain-of-function mutations in exon 11, and less frequently in exons 9, 13 and 17 may be involved in KIT overexpression in adenoid cystic carcinomas. Future studies in a larger series may be of value to determine the prognostic implications and benefits of KIT-directed therapy in tumors harboring such mutations. 
